Abstract
Tumor necrosis factor-related apoptosis-inducing ligand-receptor 1 (TRAIL-R1) and tumor necrosis factor-related apoptosis-inducing ligand-receptor 2 (TRAIL-R2) are cell-surface receptors involved in tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced cell-death signaling. TRAIL-R1 and TRAIL-R2 genes have recently been mapped to chromosome 8p21-22, which is a frequent site of allelic deletions in many types of human tumors, including non-Hodgkin's lymphoma (NHL). Because TRAIL/TRAIL receptor system plays an important role in lymphocyte homeostasis, we hypothesized that the mutations of TRAIL-R1 and TRAIL-R2 may be involved in the development of NHL and that such mutations may be responsible for the allelic losses of 8p21-22 in NHL. In this study, we analysed the entire coding region of TRAIL-R2 gene and the death domain region of TRAIL-R1 gene for the detection of the somatic mutations in a series of 117 human NHLs using polymerase chain reaction (PCR)-based single strand conformation polymorphism (SSCP) analysis. Overall, eight tumors (6.8%) were found to have two TRAIL-R1 gene mutations or six TRAIL-R2 gene mutations. Interestingly, of the eight mutations, six missense mutations (two TRAIL-R1 and four TRAIL-R2) were detected in the death domains and one nonsense mutation of TRAIL-R2 was detected just before the death domain. Our data suggest that somatic mutations of TRAIL-R1 and TRAIL-R2 genes may play a role in the pathogenesis of some NHLs and that TRAIL-R1 and TRAIL-R2 genes might be the relevant genes to the frequent loss of chromosome 8p21-22 in human NHL.
Similar content being viewed by others
References
Arai T, Akiyama Y, Okabe S, Saito K, Iwai T and Yuasa Y. . 1998 Cancer Lett. 133: 197–204.
Bodmer JL, Holler N, Reynard S, Vinciguerra P, Schneider P, Juo P, Blenis J and Tschopp J. . 2000 Nat. Cell Biol. 2: 241–243.
El-Naggar AK, Coombes MM, Batsakis JG, Hong WK, Goepfert H and Kagan J. . 1998 Oncogene 16: 2983–2987.
Emi M, Fujiwara Y, Nakajima T, Tsuchiya E, Tsuda H, Hirohashi S, Maeda Y, Tsuruta K, Miyaki M and Nakamura Y. . 1992 Cancer Res. 52: 5368–5372.
Fujiwar Y, Ohata H, Kuroki T, Koyama K, Tsuchiya E, Monden M and Nakamura Y. . 1995 Oncogene 10: 891–895.
Griffith TS, Chin WA, Jackson GC, Lynch DH and Kubin MZ. . 1998 J. Immunol. 161: 2833–2840.
Griffith TS and Lynch DL. . 1998 Curr. Opin. Immunol. 10: 559–563.
Grønbaek K, Straten PT, Ralfkiaer E, Ahrenkiel V, Andersen MK, Hansen NE, Zeuthen J, Hou-Jensen K and Guldberg P. . 1998 Blood 92: 3018–3024.
Harris NL, Jaffe ES, Stein H, Banks PM, Chan JK, Cleary ML, Delsol G, De Wolf-Peeters C, Falini B, Gatter KC, Grogan TM, Isaacson PG, Knowles DM, Mason DY, Muller-Hermelink H-K, Pileri SA, Piris MA, Ralfkiaer E and Warnke RA. . 1994 Blood 84: 1361–1392.
Kagan J, Stein J, Babaian RJ, Joe YS, Pisters LL, Glassman AB, von Eschenbach AC and Troncoso P. . 1995 Oncogene 11: 2121–2126.
Keane MM, Ettenberg SA, Nau MM, Russell EK and Lipkowitz S. . 1999 Cancer Res. 59: 734–741.
Kim KH, Fisher MJ, Xu SQ, El-Deiry WS. . 2000 Clin. Cancer Res. 6: 335–346.
Lee JY, Dong SM, Kim SY, Yoo NJ, Lee SH and Park WS. . 1998 Virchows Arch. 433: 305–309.
Lee SH, Shin MS, Kim HS, Lee HK, Park WS, Kim SY, Lee JH, Han SY, Park JY, Oh RR, Jang JJ, Han JY, Lee JY and Nam JY. . 1999a Cancer Res. 59: 5683–5686.
Lee SH, Shin MS, Park WS, Kim SY, Dong SM, Pi JH, Lee HK, Kim HS, Jang JJ, Kim CS, Kim SH, Lee JY and Yoo NJ. . 1999b Cancer Res. 59: 3068–3072.
Lee SH, Shin MS, Park WS, Kim SY, Kim HS, Han JY, Park GS, Dong SM, Pi JH, Kim CS, Kim SH, Lee JY and Yoo NJ. . 1999c Oncogene 18: 3754–3760.
MacFarlane M, Ahmad M, Srinivasula SM, Fernades-Alnemri T, Cohen GM and Alnemri ES. . 1997 J. Biol. Chem. 272: 25417–25420.
MagGrogan D, Levy A, Bova GS, Isaacs WB and Bookstein R. . 1996 Genomics 35: 55–65.
Mariani SM and Krammer PH. . 1998a Eur. J. Immunol. 28: 1494–1498.
Mariani SM and Krammer PH. . 1998b Eur. J. Immunol. 28: 973–982.
Marsters SA, Sheridan JP, Pitti RM, Huang A, Skubatch M, Baldwin D, Yuan J, Gurney A, Goddard AD, Godwski P and Ashkenazi A. . 1997 Curr. Biol. 7: 1003–1006.
Martinez-Lorenzo MJ, Alava MA, Gamen S, Kim KJ, Chuntharapal A, Pineiro A, Naval J and Anel A. . 1998 Eur. J. Immunol. 28: 2714–2725.
Mitelman F, Mertens F and Johansson B. . 1997 Nat. Genet. 15: 417–474.
Monni O, Joensuu H, Franssila K and Knuutila S. . 1996 Blood 87: 5269–5278.
Mori S, Murakami-Mori K, Nakamura S, Ashkenazi A and Bonavida B. . 1999 J. Immunol. 162: 5616–5623.
Nagata S. . 1997 Cell 88: 355–365.
Pan G, O'Rourke K, Chinnaiyan AM, Gentz R, Ebner R, Ni J and Dixit VM. . 1997 Science 276: 111–113.
Pai SI, Wu GS, Ozoren N, Wu L, Jen J, Sidransky D and El-Deiry WS. . 1998 Cancer Res. 58: 3513–3518.
Schneider P, Thome M, Burns K, Bodmer J-L, Hofmann K, Kataoka T, Holler N and Tschopp J. . 1997 Immunity 7: 831–836.
Sheridan JP, Marsters SA, Pitti RM, Gurney A, Skubatch M, Baldwin D, Ramakrishnan L, Gray CL, Baker K, Wood WI, Goddard AD, Godowski P and Ashkenazi A. . 1997 Science 277: 818–821.
Shin MS, Park WS, Kim SY, Kanf SJ, Song KY, Park JY, Dong SM, Pi JH, Oh RR, Lee JY, Yoo NJ and Lee SH. . 1999 Am. J. Pathol. 154: 1785–1791.
Snell V, Clodi K, Zhao S, Goodwin R, Thomas EK, Morris SW, Kadin ME, Cabanillas F, Andreeff M and Younes A. . 1997 Br. J. Haematol. 99: 618–624.
Thomas WD and Hersey P. . 1998 J. Immunol. 161: 2195–2220.
Walczak H, Degli-Esposti MA, Johnson RS, Smolak PJ, Waugh JY, Boiani N, Timour MS, Gerhart MJ, Schooley KA, Smith CA, Goodwin RG and Rauch CT. . 1997 EMBO J. 16: 5386–5397.
Wistuba II, Behrens C, Virmani AK, Milchgrub S, Syed S, Lam S, Mackay B, Minna JD and Gazdar AF. . 1999 Cancer Res. 59: 1973–1979.
Yaremko ML, Kutza C, Lyzak J, Mick R, Recant WM and Westbrook CA. . 1996 Genes Chromosomes Cancer 16: 189–195.
Zhang XD, Franco A, Myers K, Gray C, Nguyen T and Hersey P. . 1999 Cancer Res. 59: 2747–2753.
Acknowledgements
This work was supported by grant (No. 1999-2-20700-002-5) from the Basic Research Program of the Korea Science & Engineering Foundation.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Lee, S., Shin, M., Kim, H. et al. Somatic mutations of TRAIL-receptor 1 and TRAIL-receptor 2 genes in non-Hodgkin's lymphoma. Oncogene 20, 399–403 (2001). https://doi.org/10.1038/sj.onc.1204103
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1204103
- Springer Nature Limited
Keywords
This article is cited by
-
Harnessing TRAIL-induced cell death for cancer therapy: a long walk with thrilling discoveries
Cell Death & Differentiation (2023)
-
Targeting cell death signalling in cancer: minimising ‘Collateral damage’
British Journal of Cancer (2016)
-
Genetic association between TRAIL-R1 Thr209Arg and cancer susceptibility
Scientific Reports (2015)
-
Mutation screening of exon 9 of DR5 receptor in patients with breast cancer using PCR-SSCP
Comparative Clinical Pathology (2015)
-
Tumor Necrosis Factor-Related Apoptosis Inducing Ligand Gene Polymorphisms are Correlated with Gastric Cancer in Central China
Pharmaceutical Research (2015)